Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
OGNNEW YORK and NEW ORLEANS, Nov. 7, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Organon & Co. (NYSE: OGN). Such investors are advised to...
US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
OGN(NYSE:OGN) SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--FDA Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp)
NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation
OGNSAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Organon & Co. (NYSE: OGN). Investors who purchased shares of Organon & Co. (NYSE: OGN) prior to October 2024 and continue to hold any of those...
ROSEN, A RANKED AND LEADING FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN
OGNNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN
OGNNEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN
OGNNEW YORK CITY and NEW ORLEANS, June 17, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company’s securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
DEADLINE ALERT for OGN, RCAT, FTRE: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
OGNBENSALEM, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit
OGNNEW YORK, June 16, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the Class Period), of the important July 22, 2025 lead...
Class Action Filed Against Organon & Co. (OGN) - July 22, 2025 Deadline to Join – Contact Levi & Korsinsky
OGNNEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. (Organon or the Company) (NYSE: OGN) of a class action securities lawsuit.
Class Action Filed Against Organon & Co. (OGN) - July 22, 2025 Deadline to Join – Contact Levi & Korsinsky
OGNNEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. (Organon or the Company) (NYSE: OGN) of a class action securities lawsuit.
OGN SHAREHOLDERS: Organon & Co. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 22 Deadline (NYSE:OGN)
OGNOrganon & Co. investors that lost money are notified to contact BFA Law before July 22, 2025 securities fraud class action deadline.
OGN LAWSUIT ALERT: The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline
OGNNEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN).
OGN LAWSUIT ALERT: The Gross Law Firm Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline
OGNNEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN).
Samsung Bioepis And Organon Say FDA Designates HADLIMA High- And Low-Concentration Autoinjectors And High-Concentration Prefilled Syringe As Interchangeable Biosimilars To Humira
OGNPiper Sandler Maintains Overweight on Organon, Lowers Price Target to $18
OGNMorgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $10
OGNOrganon's Board Of Directors Cuts Quarterly Dividend To $0.02 Per Share Down From $0.28 Per Share, Company Resets Capital Allocation Priorities To Accelerate Progress Towards Deleveraging; New Annual Regular Dividend Rate Of $0.08 Per Share
OGNOrganon Affirms FY2025 Sales Guidance of $6.13B-$6.33B vs $6.23B Est
OGNOrganon Q1 2025 Adj. EPS $1.02 Beats $0.90 Estimate, Sales $1.51B Inline
OGNOrganon Reports Health Canada Approves NDUVRA, 1%, For The Topical Treatment Of Plaque Psoriasis In Adults
OGNMorgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $15
OGNOrganon And Shanghai Henlius Biotech Announced That The European Medicines Agency Has Validated The Marketing Authorization Application For HLX11, An Investigational Biosimilar Of Perjeta (pertuzumab)
OGNReported Saturday, Organon's VTAMA Phase 3 Data Shows 84% Of Patients Maintained Mild Disease After 80-Day Off-Treatment Interval In Adults And Children 2+
OGNBarclays Maintains Overweight on Organon, Lowers Price Target to $24
OGNMorgan Stanley Maintains Equal-Weight on Organon, Lowers Price Target to $16
OGNOrganon Expects 2025 Sales Of $6.125B-$6.325B Versus Consensus Of $6.471B
OGNOrganon Q4 2024 Adj EPS $0.90 Beats $0.87 Estimate, Sales $1.59B Inline
OGNThe FDA Has Extended The Target Action Date Of Its Review Of Organon's Supplemental New Drug Application For Vtama (Tapinarof) Cream, 1% For Atopic Dermatitis In Adults And Children Two Years Of Age And Older. The New Target Date Is March 12, 2025, Revise
OGNOrganon Expects 2024 Adjusted EBITDA Margin Of 30%-31% Compared To Prior Guidance Of 31%-33%
OGNOrganon Expects 2024 Revenues Of $6.375B-$6.425B Versus Prior Guidance Of $6.25B-$6.45B And Consensus Of $6.382B
OGNOrganon Q3 2024 Adj EPS $0.87 Misses $0.90 Estimate, Sales $1.58B Beat $1.56B Estimate
OGN